| Revenue growth | 11.5% YoY for FY26; 17.4% for Q4 FY26. |
|---|---|
| Margins | FY26 EBITDA margin improved to 12.4% from 10.7%. |
| Demand visibility | Strong traction in non-Ibuprofen APIs; Ibuprofen demand stabilized post-destocking. |
| Management confidence | High; confident in sustaining growth momentum via product diversification. |
Growth
FY26 Revenue grew 11.5% to ₹2,319cr; EBITDA rose 29% to ₹290cr; PAT increased 36% to ₹138cr.
Outlook
Guided mid-to-high teens revenue growth for FY27; ₹1,200-1,400cr greenfield capex planned over 4-5 years.
Risks
Geopolitical volatility, rising raw material costs, and logistics delays affecting global supply chains.
Earnings Call filed with BSE, NSE: IOLCP. Summary written with AI assistance from the document.
IOL Chemicals and Pharmaceuticals Ltd: key numbers
- Share price
- ₹204.19
- Market cap
- ₹5,994 Cr
- Revenue (annual)
- ₹2,319 Cr
- Net profit (annual)
- ₹137.6 Cr
- P/E (TTM)
- 35.6×Sector 50.4×
- Promoter holding
- 62.28%+4.80% QoQ
- FII holding
- 4.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from IOL Chemicals and Pharmaceuticals Ltd
All →IOL Chemicals and Pharmaceuticals Regulatory Approval
IOL Chemicals and Pharmaceuticals Limited received EU-REACH registration for its product 'Triacetin', enabling the company to export this product to countries in the European Union.
IOL Chemicals and Pharmaceuticals Other Announcement
IOL Chemicals and Pharmaceuticals Limited informed the Exchange about the dispatch of reminder letters to shareholders holding physical shares for updating their KYC details.
IOL Chemicals and Pharmaceuticals Earnings Call Transcript: Key Takeaways
IOL Chemicals announced three strategic initiatives involving INR 500 Cr investment: Ibuprofen capacity expansion (to 18,000 MTPA), a new CDMO formulations facility, and a dedicated specialty chemical tolling facility.
- Call
- Guides 20% growth
IOL Chemicals and Pharmaceuticals Capacity Expansion: ₹350 Cr Investment
IOL Chemicals and Pharmaceuticals Ltd will expand Ibuprofen capacity by 6,000 MTPA. The project, requiring a ₹350 Crore investment, is expected to be commercialized by December 2027.
- Value
- ₹350.0 Cr
- Execution
- December 2027
- manufacturing capacity
- 6000.0 MTPA
IOL Chemicals and Pharmaceuticals Capacity Expansion: ₹495 Cr Investment
IOLCP announces three capacity expansions at Barnala: 6,000 MTPA Ibuprofen unit, CDMO formulation facility, and specialty chemicals tolling plant. Total investment ₹495 Crore funded via internal accruals.
- Value
- ₹495.0 Cr
- ibuprofen manufacturing capacity
- 6000 MTPA
IOL Chemicals and Pharmaceuticals Annual General Meeting
IOL Chemicals and Pharmaceuticals Limited held its 39th Annual General Meeting on September 2, 2026. Members approved the audited financial statements and director re-appointment with requisite majority.